Results 171 to 180 of about 15,200 (191)

Daratumumab

Reactions Weekly, 2017
openaire   +2 more sources

Daratumumab monotherapy for refractory lupus nephritis

Nature Medicine, 2023
Dario Roccatello, Savino Sciascia
exaly  

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Journal of Clinical Oncology, 2022
Luciano J Costa, Saurabh Chhabra, Eva Medvedova   +2 more
exaly  

Daratumumab Immunopolymersome‐Enabled Safe and CD38‐Targeted Chemotherapy and Depletion of Multiple Myeloma

Advanced Materials, 2021
Fenghua Meng, Huanli Sun, Rainer Haag
exaly  

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

Lancet Oncology, The, 2022
Saad Z Usmani, Hang Quach, María-Victoria Mateos   +2 more
exaly  

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Lancet Oncology, The, 2021
Phillipe Moreau, Bertrand Arnulf, Hélène Caillon   +2 more
exaly  

Daratumumab

Reactions Weekly, 2018
  +4 more sources

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Lancet, The, 2020
María-Victoria Mateos, Michele Cavo, 鈴木 憲史   +2 more
exaly  

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Lancet Haematology,the, 2020
María-Victoria Mateos, Hareth Nahi, Sebastian Grosicki   +2 more
exaly  

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Lancet, The, 2019
Phillipe Moreau, Michel M Attal, `Cyrille Hulin   +2 more
exaly